David Y. Liu - Nov 16, 2022 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief R&D Strategy Officer
Signature
/s/ Asif Ali, Attorney-in-Fact for David Y. Liu
Stock symbol
PTGX
Transactions as of
Nov 16, 2022
Transactions value $
$231,802
Form type
4
Date filed
11/17/2022, 05:24 PM
Previous filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $12K +13.8K +20.51% $0.87* 80.9K Nov 16, 2022 Direct F1
transaction PTGX Common Stock Options Exercise $18.4K +9.73K +12.03% $1.89* 90.6K Nov 16, 2022 Direct
transaction PTGX Common Stock Options Exercise $11.3K +6K +6.62% $1.89* 96.6K Nov 16, 2022 Direct
transaction PTGX Common Stock Options Exercise $41.4K +35.7K +36.91% $1.16* 132K Nov 16, 2022 Direct
transaction PTGX Common Stock Options Exercise $149K +35.3K +26.71% $4.21* 168K Nov 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -13.8K -100% $0.00* 0 Nov 16, 2022 Common Stock 13.8K $0.87 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -9.73K -100% $0.00* 0 Nov 16, 2022 Common Stock 9.73K $1.89 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -6K -100% $0.00* 0 Nov 16, 2022 Common Stock 6K $1.89 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -35.7K -100% $0.00* 0 Nov 16, 2022 Common Stock 35.7K $1.16 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -35.3K -100% $0.00* 0 Nov 16, 2022 Common Stock 35.3K $4.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 573 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022 and September 9, 2022.
F2 The stock option is vested in full.

Remarks:

Exhibit 24 - Power of Attorney